The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808.
“FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to b